Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

AADI - Aadi Bioscience, Inc.

IEX Last Trade
3.02
0   0%

Share volume: 441,740
Last Updated: Mon 13 Jan 2025 10:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): -0.38%

PREVIOUS CLOSE
CHG
CHG%
$3.02
-0.58
-0.16%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
9%
Profitability 0%
Dept financing 23%
Liquidity 72%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-16.11%
1 Month
26.89%
3 Months
40.47%
6 Months
102.68%
1 Year
84.15%
2 Year
-76.68%
Key data
Stock price
$3.02
P/E Ratio 
0.00
DAY RANGE
$3.00 - $3.59
EPS 
$0.00
52 WEEK RANGE
$1.41 - $3.81
52 WEEK CHANGE
$84.15
MARKET CAP 
50.707 M
YIELD 
N/A
SHARES OUTSTANDING 
24.615 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
1.46
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$481,369
AVERAGE 30 VOLUME 
$919,994
Company detail
CEO: Neil P. Desai
Region: US
Website: aadibio.com
Employees: 40
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin.

Recent news